COMMUNIQUÉS West-GlobeNewswire

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
28/04/2026
New Taipei City, Taiwan, April 28, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization [...]
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
28/04/2026
New acquisitions from Rain Foundation underlines Enlivex’s disciplined prediction markets treasury strategy Nes-Ziona, Israel, April 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), [...]
Prodeon Medical Highlights the Urocross Expander System Clinical Results at the American Urological Association (AUA) 2026 Annual Meeting
28/04/2026
Company’s prospective, multi-center 240-patient, pivotal randomized controlled trial (RCT) earns AUA “Practice-changing, Paradigm-shifting Clinical Trials in Urology (P2s)” designation at conference’s Plenary Session [...]
Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
28/04/2026
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place [...]
Playground Pediatrics Expands Pediatric Access Across Four States
28/04/2026
High-quality pediatric care is growing in Georgia, North Carolina, Pennsylvania, and Tennessee NASHVILLE, Tenn., April 28, 2026 (GLOBE NEWSWIRE) -- Playground Pediatrics, a physician-led pediatric primary care services [...]
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
28/04/2026
- Orphan drug designation from the European Commission underscores Solid’s commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy - CHARLESTOWN, Mass., [...]
Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
28/04/2026
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita Study Will be Led [...]
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
28/04/2026
Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegeneration Buntanetap was safe and well-tolerated, including [...]
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
28/04/2026
SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended [...]
electroCore to Present at the Market Movers Investor Summit on May 5, 2026
28/04/2026
ROCKAWAY, N.J., April 28, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in the Market Movers [...]
Cynet Launches New Capabilities for CyAI Engine That Improves Itself Over Time
28/04/2026
New AI capabilities create a feedback loop where analyst input and automated analysis continuously improve threat detection and response BOSTON, April 28, 2026 (GLOBE NEWSWIRE) -- Cynet, the unified, AI-powered [...]
ExamWorks Announces Appointment of Isabelle Winkles as Chief Financial Officer to Support Continued Growth and Strategic Execution
28/04/2026
ATLANTA, GA, April 28, 2026 (GLOBE NEWSWIRE) -- ExamWorks Group (“ExamWorks”), a leading global provider of medical claims management solutions, including independent medical examinations, peer reviews, record retrieval [...]
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
28/04/2026
– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 [...]
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures
28/04/2026
SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today [...]
Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026
28/04/2026
The Company will Host a Conference Call and Webcast on May 12, 2026, at 8:30 AM ET CORAL GABLES, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a [...]
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
28/04/2026
Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to lower hospital resource utilization following abdominal colorectal surgery PETACH TIKVA, Israel, [...]
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
28/04/2026
With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track [...]
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White
28/04/2026
- New national campaign encourages recognition of ATTR-CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1 PALO ALTO, Calif., April 28, 2026 (GLOBE NEWSWIRE [...]
Kestrel Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of KST-6051, a Potential Best-in-Class Pan-KRAS Inhibitor, in Patients with KRAS-driven Malignancies
28/04/2026
Kestrel has entered into a warrant agreement with AbbVie with an exclusive option for AbbVie to acquire the Company based on defined development milestones WATERTOWN, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Kestrel [...]

Pages